Population Screening and Treatment of LTBI in TB Control in the US
TB Prevention and Control in the United States
Therapy for Latent Tuberculosis Infection
Reported TB Cases per
100,000 Population
United States, 1953 – 2000
Factors Affecting the Impact of TTTLTBI
The Tuberculin Skin Test (TST)
Positive Predictive Value
of a Tuberculin Test
Am J Respir Crit Care Med; 2000, Vol 161, p 1389
Tuberculosis Screening in Private Physicians' Offices, Pennsylvania, 1996
Learning
Objective
(QuantiFERON)
Factors Affecting the Impact TTTLTBI
Risk of TB Disease by Time of M. tb Infection
Factors Affecting the Impact of TTTLTBI
Issues Associated With Completion of TLTBI
A Tuberculin Screening and Isoniazid Preventive Therapy Program in an Inner-city Population
Optimal Duration of INH Therapy for the TLTBI, MMWR 2000;49(No.6)
Effect of the Duration of INH Therapy on the Prevention of Active TB
How Much Isoniazid Is Needed for the Prevention of Tuberculosis?
Percentage of Infected
Contacts
Age 15 - 34
Completing Treatment for LTBI
Isoniazid Preventive
Therapy
HIV Infection - TST Positive
Short-Course
Regimens
HIV Infection - TST Positive
Problems Associated with TLTBI
USPHS Study 26: Highly intermittent short-course treatment of LTBI
Factors Affecting the Impact of TTTLTBI
Toxicity of Isoniazid in Persons Without HIV Infection
Reports of Severe Liver
Injury Associated
with RZ Treatment of LTBI
October 2000 – May 23, 2002